Bruker Corporation has unveiled the Beacon Discovery™ Optofluidic System, designed to democratize live single-cell functional analysis. Officially introduced at the AACR Annual Meeting 2025, this benchtop system delivers high-precision single-cell control and analysis at a reduced cost of ownership, making it a powerful addition to any research lab.

Built on Bruker's proven Opto-Electrical Positioning (OEP) technology and OptoSelect™ microfluidic chips, Beacon Discovery enables multi-parameter and longitudinal studies, combining real-time imaging and sequential assays over days or weeks. Researchers can recover cells post-analysis for downstream genomic and transcriptomic profiling, linking functional performance directly to molecular signatures.

Ideal for academic and biotech researchers, Beacon Discovery offers an intuitive interface and customizable workflows to advance work in immuno-oncology, infectious diseases, autoimmune disorders, and regenerative medicine.

Key Features of the Beacon Discovery Optofluidic System:

• Proprietary Opto-Electrical Positioning (OEP) for precise single-cell control

• Integrated live-cell imaging and multi-day functional assays

• Scalable OptoSelect™ microfluidic chip platform

• Easy-to-use interface with customizable research workflows

• Reduced operating and ownership costs for broader accessibility

• Seamless cell recovery for downstream transcriptomic/genomic analysis

With commercial shipments expected later in 2025, Beacon Discovery is now open for pre-orders, alongside an exclusive Technology Access Program (TAP) offering sample evaluations.